Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
PLoS Global Public Health ; 2(1), 2022.
Article in English | CAB Abstracts | ID: covidwho-1854933


Introduction: Clostridioides difficile is primarily associated with hospital-acquired diarrhoea. The disease burden is aggravated in patients with comorbidities due to increased likelihood of polypharmacy, extended hospital stays and compromised immunity. The study aimed to investigate comorbidity predictors of healthcare facility-onset C. difficile infection (HO-CDI) in hospitalized patients. Methodology: We performed a cross sectional study of 333 patients who developed diarrhoea during hospitalization. The patients were tested for CDI. Data on demographics, admission information, medication exposure and comorbidities were collected. The comorbidities were also categorised according to Charlson Comorbidity Index (CCI) and Elixhauser Comorbidity Index (ECI). Comorbidity predictors of HO-CDI were identified using multiple logistic regression analysis.

CHEST ; 161(1):A233-A233, 2022.
Article in English | Academic Search Complete | ID: covidwho-1625739
Asian Journal of Pharmaceutical and Clinical Research ; 14(12):64-68, 2021.
Article in English | EMBASE | ID: covidwho-1579464


Objective: This study aims to study the demographic analysis, clinical characteristics, diagnosis, and management in COVID-19 patients and assess the complications in COVID-19 patients. Methods: A retrospective observational single centered study is carried out to study the demographic analysis, clinical characteristics, diagnosis, management, and complications in COVID-19 patients. Results: Among 100 COVID-19 patients, 58% were male and 42% were female. Percentages of age group between 60-70 years (27%), 50-60 (20%), 40-50 (16%), 70-80 (16%), 30-40 (8%), 20-30 (5%), 80-90 (4%), and 10-20 (4%). Co-morbidities were diabetes (44%), hypertension (HTN) (28%), coronary artery disease (21%), thyroid (19%), chronic obstructive pulmonary disease (12%), anemia (8%), and renal impairment (4%). Signs and symptoms were fever (88%), cough (80%), shortness of breath (72%), fatigue (68%), myalgia (60%), loss of appetite (52%), cold (24%), loss of smell and taste (20%), diarrhea and vomiting (12%). (97%) of the patients had two or more symptoms. Diagnostic test include reverse transcription polymerase chain reaction (RT-PCR) (100%), high-resolution computed tomography (HRCT) (100%), O2 saturation (99%), D-dimer (65%), c-reactive (60%), Procalcitonin (60%), and also lactate dehydrogenase, interleukin-6, prothrombin time, international normalized ratio, ferritin, complete blood count, white blood cell. Treatment includes antiviral (100%), antibiotics (100%), corticosteroids (73%), immunosuppressant (54%), and antihypertensive, antidiabetic, antiplatelets, bronchodilators, vitamins, and mineral supplements. Conclusion: COVID-19 infects the males more and average ages of 65 years are at risk. HTN and diabetes were most common co-morbid condition. Fever and cough are major followed by weakness sob and cold. RT-PCR and HRCT are accurate tool to detect COVID-19. Although standard treatment is not yet available antibiotics and antiviral are used followed by corticosteroids. The majority of the patients have mild and moderate injection and with the lowest death rate. Older age and co-morbid conditions are major risk factors.